

# Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

<https://marketpublishers.com/r/PBD0FB29823EN.html>

Date: January 2024

Pages: 157

Price: US\$ 5,500.00 (Single User License)

ID: PBD0FB29823EN

## Abstracts

### Report Scope:

This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.

### Report Includes:

31 data tables and 63 additional tables

An overview of the global market for the technologies for prevention and treatment of prostate cancer

Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028

Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region

Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas

Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations

Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer

Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer

Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios

Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer

Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies

Profiles of leading market participants

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing this Study  
Scope of Report  
What's New in this Update?  
Methodology and Information Sources  
Geographic Breakdown  
Segmentation Breakdown

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

Market Outlook  
Market Summary

### **CHAPTER 3 MARKET OVERVIEW**

Overview of Cancer  
Prostate Cancer  
Biology of Prostate Cancer  
Symptoms  
Screening  
Diagnosis  
Localized Prostate Cancer  
Metastatic Prostate Cancer  
Watchful Waiting or Active Surveillance  
Treatment  
Conclusions

### **CHAPTER 4 MARKET DYNAMICS**

Overview  
Market Drivers  
Increasing Prevalence of Prostate Cancer  
Active Surveillance and Screening  
Personalized Care  
Approvals for Metastatic Castration-Resistant Prostate Cancer

Collaborations and Licensing Agreements  
Market Challenges  
Loss of Exclusivity and Genericization  
Shortage of Care Providers and Other Resources  
Market Opportunities

## **CHAPTER 5 SCREENING AND DIAGNOSIS MARKET BY TEST TYPE**

Market Overview  
Biomarker Tests  
PSA Tests  
Limitations of PSA Tests  
Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings  
Digital Rectal Exam  
Limitations of DREs  
Prostate Biopsy  
Grade (Gleason Score) of Prostate Cancer  
Prostatic Intraepithelial Neoplasia  
Atypical Small Acinar Proliferation  
Proliferative Inflammatory Atrophy  
Intraductal Carcinoma of the Prostate  
Limitations of Prostate Biopsies  
Imaging Technologies for Prostate Cancer  
Market for Prostate Cancer Screening/Diagnosis, by Test Type  
Biomarker Tests  
DREs  
Prostate Biopsies

## **CHAPTER 6 PHARMACEUTICALS MARKET BY DRUG TYPE**

Market Overview  
Hormone Therapy  
Androgen Deprivation Therapy  
Antiandrogen Therapies  
Hormone Therapy Uses in Prostate Cancer Treatment  
Targeted Therapy  
PARP Inhibitors  
Radioligand Therapies  
Small Molecule Targeted Agents

Monoclonal Antibodies  
Chemotherapy  
Immunotherapy  
Market Revenue, by Drug Type  
Hormone Therapy  
Targeted Therapy  
Immunotherapy  
Chemotherapy

## **CHAPTER 7 MARKET FOR SURGERY AND RADIATION THERAPY BY TREATMENT TYPE**

Market Overview  
Active Surveillance  
Radical Prostatectomy  
Robotic Prostatectomy  
Open Radical Prostatectomy  
Laparoscopic Prostatectomy  
Radical Prostatectomy Market Revenue  
Radiation Therapy  
External Beam Radiation Therapy  
Brachytherapy  
Combined Radiation Therapy  
Radiation Therapy Device Market Revenue

## **CHAPTER 8 MARKET BREAKDOWN BY REGION**

Market Overview  
Market Revenue, by Region  
North America  
Market Revenue, by Product Type  
Europe  
Market Revenue, by Product Type  
Asia-Pacific  
Market Revenue, by Product Type  
Rest of the World (RoW)  
Market Revenue, by Product Type

## **CHAPTER 9 EMERGING TECHNOLOGIES AND DEVELOPMENTS**

Overview  
Liquid Biopsy  
Multiparametric MRI  
Homologous Recombination Repair Gene Mutation  
Advanced Radiotherapy Techniques  
AI and Machine Learning

## **CHAPTER 10 PIPELINE ANALYSIS**

Overview  
By Company

## **CHAPTER 11 COMPETITIVE INTELLIGENCE**

Overview  
Screening and Diagnosis Market  
Market for Radiation Therapy Devices  
Pharmaceuticals Market

## **CHAPTER 12 COMPANY PROFILES**

ABBOTT  
ACCURAY INC.  
ASTELLAS PHARMA INC.  
ASTRAZENECA PLC  
BAYER AG  
DANAHER CORP.  
DENDREON PHARMACEUTICALS LLC  
ELEKTA  
F. HOFFMANN-LA ROCHE LTD.  
JOHNSON & JOHNSON SERVICES INC.  
PFIZER INC.  
SANOFI  
SIEMENS HEALTHINEERS AG

## **CHAPTER 13 APPENDIX: ABBREVIATIONS**

## List Of Tables

### LIST OF TABLES

Summary Table : Global Market for Prostate Cancer Care, by Type, Through 2028

Table 1 : Four Stages of Prostate Cancer

Table 2 : Prostate Cancer: Local and Metastatic Symptoms

Table 3 : Current Prostate Cancer Treatment Options

Table 4 : Prostate Cancer: Major Points

Table 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 to 2040

Table 6 : Key Biomarkers for Prostate Cancer

Table 7 : First-Time Generic Drug Approvals for Prostate Cancer, 2021 to November 2023

Table 8 : ACS, NCCN and USPSTF Guidelines on PSA Screening Tests

Table 9 : Additional Biomarker Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings

Table 10 : NCCN and USPSTF Guidelines on Use of DRE for Prostate Cancer Screening

Table 11 : Imaging Technologies for Prostate Cancer

Table 12 : Prostate Cancer Screening and Diagnostic Methods

Table 13 : Global Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028

Table 14 : Hormone Therapy Drugs Approved for Prostate Cancer Treatment

Table 15 : PARP Inhibitors Approved for Prostate Cancer Treatment

Table 16 : Radioligand Drugs Approved for Prostate Cancer Treatment

Table 17 : Chemotherapy Drugs Approved for Prostate Cancer Treatment

Table 18 : Immunotherapy Approved for Prostate Cancer Treatment

Table 19 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, Through 2028

Table 20 : Global Market for Hormone Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028

Table 21 : Global Market for Targeted Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028

Table 22 : Treatment Options for Prostate Cancer

Table 23 : Advantages and Disadvantages of Radical Prostatectomy

Table 24 : Global Market for Radical Prostatectomy, Through 2028

Table 25 : Comparison of Low- and High-Dose Radiation Therapy

Table 26 : Comparison of EBRT and Brachytherapy

Table 27 : Global Market for Radiation Therapy Devices for Prostate Cancer, by

Treatment Type, Through 2028

Table 28 : Advances in EBRT

Table 29 : Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region, Through 2028

Table 30 : North American Market for Prostate Cancer Care, by Product Type, Through 2028

Table 31 : North American Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028

Table 32 : Europe: Prostate Cancer Incidence, Mortality and Prevalence, 2020

Table 33 : European Market for Prostate Cancer Care, by Product Type, Through 2028

Table 34 : European Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028

Table 35 : Worldwide Number of New Prostate Cancer Cases, by Region, 2020, 2030, 2040

Table 36 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, Through 2028

Table 37 : Asia-Pacific Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028

Table 38 : RoW Market for Prostate Cancer Care, by Product Type, Through 2028

Table 39 : Liquid Biopsy Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings

Table 40 : PARP Inhibitors in Phase 3 Clinical Trials

Table 41 : Companies with Two or More Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Company, as of November 2023

Table 42 : Prostate Cancer Drugs Pipeline (Phase III Industry Trials)

Table 43 : Ranking of Companies in the Market for Biomarker Tests for Prostate Cancer Screening and Diagnosis, 2022

Table 44 : Ranking of Companies in the Market for Radiation Therapy Devices for Prostate Cancer, 2022

Table 45 : Abbott: Company Snapshot

Table 46 : Abbott: Financial Performance, FY 2021 and 2022

Table 47 : Abbott: Prostate Cancer Product Portfolio

Table 48 : Accuracy Inc.: Company Snapshot

Table 49 : Accuracy Inc.: Financial Performance, FY 2022 and 2023

Table 50 : Accuray Inc.: Radiotherapy Product Portfolio

Table 51 : Accuray Inc.: Recent Developments, 2022-2023

Table 52 : Astellas Pharma Inc.: Company Snapshot

Table 53 : Astellas Pharma Inc.: Financial Performance, FY 2021 and 2022

Table 54 : Astellas Pharma Inc.: Prostate Cancer Drug Portfolio



- Table 55 : Astellas Pharma Inc.: Recent Developments, 2021-2023
- Table 56 : AstraZeneca Plc: Company Snapshot
- Table 57 : AstraZeneca Plc: Financial Performance, FY 2021 and 2022
- Table 58 : AstraZeneca Plc: Prostate Cancer Drug Portfolio
- Table 59 : AstraZeneca Plc: Recent Developments, 2022-2023
- Table 60 : Bayer AG: Company Snapshot
- Table 61 : Bayer AG: Financial Performance, FY 2021 and 2022
- Table 62 : Bayer AG: Prostate Cancer Drugs Portfolio
- Table 63 : Bayer AG: Recent Developments, 2021-2023
- Table 64 : Danaher Corp.: Company Snapshot
- Table 65 : Danaher Corp.: Financial Performance, FY 2021 and 2022
- Table 66 : Danaher Corp.: Prostate Health Product Portfolio
- Table 67 : Dendreon Pharmaceuticals LLC: Company Snapshot
- Table 68 : Dendreon Pharmaceuticals LLC: Prostate Cancer Drug Portfolio
- Table 69 : Elekta: Company Snapshot
- Table 70 : Elekta: Financial Performance, FY 2022 and 2023
- Table 71 : Elekta: Radiotherapy Product Portfolio
- Table 72 : Elekta: Recent Developments, 2021-2023
- Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2021 and 2022
- Table 75 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 76 : F. Hoffmann-La Roche Ltd.: Recent Developments, 2023
- Table 77 : Johnson & Johnson Services, Inc.: Company Snapshot
- Table 78 : Johnson & Johnson Services, Inc.: Financial Performance, FY 2021 and 2022
- Table 79 : Johnson & Johnson Services, Inc.: Prostate Cancer Drug Portfolio
- Table 80 : Johnson & Johnson Services, Inc.: Recent Developments, 2023
- Table 81 : Pfizer Inc.: Company Snapshot
- Table 82 : Pfizer Inc.: Financial Performance, FY 2021 and 2022
- Table 83 : Pfizer Inc.: Prostate Cancer Drugs Portfolio
- Table 84 : Pfizer Inc.: Recent Developments, 2022-2023
- Table 85 : Sanofi: Company Snapshot
- Table 86 : Sanofi: Financial Performance, FY 2021 and 2022
- Table 87 : Sanofi: Prostate Cancer Drug Portfolio
- Table 88 : Sanofi: Recent Developments, 2022
- Table 89 : Siemens Healthineers: Company Snapshot
- Table 90 : Siemens Healthineers: Financial Performance, FY 2022 and 2023
- Table 91 : Siemens Healthineers: Prostate Cancer Product Portfolio
- Table 92 : Siemens Healthineers: Recent Developments, 2022-2023

Table 93 : Abbreviations Used in this Report

## List Of Figures

### LIST OF FIGURES

Summary Figure A : Global Market for Prostate Cancer Care, by Type, 2020-2028

Summary Figure B : Global Market Shares of Prostate Cancer Care, by Type, 2022

Figure 1 : Cancer Care Spectrum

Figure 2 : Prostate Cancer Risk Group

Figure 3 : Prostate Cancer Advancements

Figure 4 : Prostate Cancer Care Market Dynamics

Figure 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 and 2040

Figure 6 : Share of Prostate Cancer Cases, by Stage

Figure 7 : Prostate Cancer Incidence in the U.S.

Figure 8 : Cancer Radiotherapy Systems Treatment, by Region, 2021

Figure 9 : Prostate Cancer 5-Year Relative Survival Rates

Figure 10 : Trends in Oncology

Figure 11 : Global Market for Prostate Cancer Screening and Detection, by Test Type, 2020-2028

Figure 12 : Global Market Shares of Prostate Cancer Screening and Detection, by Test Type, 2022

Figure 13 : Benefits of Immunotherapy

Figure 14 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, 2020-2028

Figure 15 : Global Market Shares of Prostate Cancer Pharmaceuticals, by Drug Type, 2022

Figure 16 : Global Market Shares of Hormone Therapy Drugs for Prostate Cancer, by Drug Type, 2022

Figure 17 : Global Market Shares of Targeted Therapy Drugs for Prostate Cancer, by Drug Type, 2022

Figure 18 : Global Market for Radical Prostatectomy, 2020-2028

Figure 19 : Types of Radiation

Figure 20 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2020-2028

Figure 21 : Global Market Shares of Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2022

Figure 22 : Snapshot of Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region

Figure 23 : Global Market Shares of Prostate Cancer Screening, Diagnosis and

Treatment, by Region, 2022

Figure 24 : Estimated Number of Prostate Cancer Cases in the U.S., Both Sexes, 2020 to 2040

Figure 25 : North American Market for Prostate Cancer Care, by Product Type, 2020-2028

Figure 26 : European Market for Prostate Cancer Care, by Product Type, 2020-2028

Figure 27 : Worldwide Distribution of New Prostate Cancer Cases, by Region, 2020-2040

Figure 28 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, 2020-2028

Figure 29 : RoW Market for Prostate Cancer Care, by Product Type, 2020-2028

Figure 30 : Emerging Technologies in Prostate Cancer Care

Figure 31 : Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Cancer Type, as of November 2023

Figure 32 : Share of Active Clinical Trials in Phase 2 or 3 for Castration-Resistant Prostate Cancer (CRPC), by Cancer Type, as of November 2023

Figure 33 : Global Market Share of Prostate Cancer Pharmaceutical, by Company, 2022

Figure 34 : Abbott: Revenue Share, by Business Unit, FY 2022

Figure 35 : Abbott: Revenue Share, by Region, FY 2022

Figure 36 : Accuray Inc.: Revenue Share, by Product Type, FY 2023

Figure 37 : Accuray Inc.: Revenue Share, by Region, FY 2023

Figure 38 : Astellas Pharma Inc.: Revenue Share, by Product, 2022

Figure 39 : Astellas Pharma Inc.: Revenue Share, by Region, 2022

Figure 40 : AstraZeneca Plc: Revenue Share, by Therapy Area, 2022

Figure 41 : AstraZeneca Plc: Revenue Share, by Region, 2022

Figure 42 : Bayer AG: Revenue Share, by Business Segment, 2022

Figure 43 : Bayer AG: Revenue Share, by Region, 2022

Figure 44 : Danaher Corp.: Market Share, by Business Segment, 2022

Figure 45 : Danaher Corp.: Revenue Share, by Region, 2022

Figure 46 : Elekta: Revenue Share, by Product Type, 2023

Figure 47 : Elekta: Revenue Share, by Region, 2023

Figure 48 : F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2022

Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022

Figure 50 : Johnson & Johnson Services, Inc.: Revenue Share, by Business Segment, 2022

Figure 51 : Johnson & Johnson Services, Inc.: Revenue Share, by Region, 2022

Figure 52 : Pfizer Inc.: Revenue Share, by Business Unit, 2022

Figure 53 : Pfizer Inc.: Revenue Share, by Region, 2022

Figure 54 : Sanofi: Revenue Share, by Global Business Unit, 2022

Figure 55 : Sanofi: Revenue Share, by Region, 2022

Figure 56 : Siemens Healthineers: Revenue Share, by Segment, 2023

Figure 57 : Siemens Healthineers: Revenue Share, by Region, 2023

## I would like to order

Product name: Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/PBD0FB29823EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PBD0FB29823EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970